Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)

SHA:688506 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6,086	3,220	403.96	1,005	154.22	47.2
Short-Term Investments	-	2,533	-	-	-	-
Trading Asset Securities	71.28	-	-	-	-	197.54
Cash & Short-Term Investments	6,157	5,753	403.96	1,005	154.22	244.74
Cash Growth	23.72%	1324.16%	-59.79%	551.49%	-36.99%	-0.83%
Accounts Receivable	1,873	138.71	137.85	267.92	134.95	226.49
Other Receivables	34.2	34.33	3.9	5.14	2.95	0.64
Receivables	1,907	173.05	141.75	273.06	137.9	227.13
Inventory	170.76	162.19	140.91	101.33	82.33	65.77
Other Current Assets	3,125	218.87	89.2	47.22	49.36	33.21
Total Current Assets	11,360	6,307	775.82	1,426	423.81	570.85
Property, Plant & Equipment	764.96	573.09	534.79	420.26	404.98	380.91
Other Intangible Assets	29	26.68	28	29.53	31.16	32.88
Long-Term Deferred Tax Assets	122.63	179.2	76.18	83.23	65.8	48.2
Long-Term Deferred Charges	21.41	18.4	1.82	1.79	1.16	0.67
Other Long-Term Assets	21.68	32.79	8.5	30.28	24.54	8.47
Total Assets	12,319	7,137	1,425	1,991	951.46	1,042
Accounts Payable	558.74	219.25	160.17	128.85	45.96	67.96
Accrued Expenses	80.5	437.25	257.88	244.81	139.81	204.43
Short-Term Debt	250.31	595.5	275.12	155.13	161.23	150.21
Current Portion of Long-Term Debt	585.59	235.28	174.37	30.47	0.02	-
Current Portion of Leases	-	20.19	46.13	68.82	24.23	-
Current Income Taxes Payable	106.3	14.13	0.01	4.96	1.54	10.31
Current Unearned Revenue	355.64	356.13	8.67	17.42	10.78	18.1
Other Current Liabilities	203.55	102.21	131.48	86.74	87.75	81.44
Total Current Liabilities	2,141	1,980	1,054	737.2	471.32	532.45
Long-Term Debt	2,810	1,189	183.92	239.96	50	-
Long-Term Leases	124.79	28.13	8.65	52.95	51.42	-
Long-Term Unearned Revenue	62.33	42.27	15.63	13.29	31.04	37.24
Long-Term Deferred Tax Liabilities	1.77	1.94	-	0.08	-	0.08
Other Long-Term Liabilities	8.71	9.73	11.19	14.05	15.81	20.14
Total Liabilities	5,148	3,251	1,273	1,058	619.61	589.91
Common Stock	412.87	401	401	401	360.9	360.9
Additional Paid-In Capital	4,649	885.84	858.69	858.55	14.17	14.07
Retained Earnings	2,104	2,599	-1,109	-328.45	-45.98	74.01
Comprehensive Income & Other	4.93	0.53	1.13	2.79	2.76	3.1
Total Common Equity	7,171	3,886	151.87	933.89	331.85	452.08
Shareholders' Equity	7,171	3,886	151.87	933.89	331.85	452.08
Total Liabilities & Equity	12,319	7,137	1,425	1,991	951.46	1,042
Total Debt	3,771	2,069	688.19	547.33	286.91	150.21
Net Cash (Debt)	2,386	3,685	-284.23	457.41	-132.69	94.53
Net Cash Growth	-30.35%	-	-	-	-	82.72%
Net Cash Per Share	5.94	9.19	-0.71	1.26	-0.37	0.27
Filing Date Shares Outstanding	412.87	401	401	401	360.9	344.56
Total Common Shares Outstanding	412.87	401	401	401	360.9	344.56
Working Capital	9,219	4,327	-278.01	689.14	-47.51	38.4
Book Value Per Share	17.37	9.69	0.38	2.33	0.92	1.31
Tangible Book Value	7,142	3,859	123.88	904.36	300.69	419.2
Tangible Book Value Per Share	17.30	9.62	0.31	2.26	0.83	1.22
Buildings	-	325.3	304.56	302.23	300.82	252.7
Machinery	-	640.12	554.25	439.83	419.75	363.73
Construction In Progress	-	35.51	81.37	67.21	18.18	76.71

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.